1 recruiting. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
Follow Phenomen Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly | Not applicable | Recruiting | Phenomen Pharma | 90 | 2025-06-19 | 2025-07-23 |
Fatty Liver (1) · Fatty Liver, Alcoholic (1) · Hepatomegaly (1) · Liver Diseases (1) · Non-alcoholic Fatty Liver Disease (1)
S-Adenosylmethionine (1) · Ursodeoxycholic Acid (1)
Russia (1)